Actavis sells Foshan Pharma stake

Share this article:

Actavis's planned China departure is gaining speed. The company announced Friday that it is selling its interest in Foshan Pharmaceuticals to Zhejiang Chiral Medicine Chemicals Co., Ltd.

The company said in a statement that its plan is to “further commercial operations in China in collaboration with its preferred business partners,” but the firm has recently been talking about how the country's business climate is not friendly enough.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters